Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: Release from adrenergic terminals and modulation by α 2-autoreceptors

Journal of Neuroscience Methods

Volumn 140, Issue 1-2 SPEC. ISS., 2004, Pages 141-152

  Gobert, Alain ^a   Billiras, Rodolphe ^a   Cistarelli, Laetitia ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Autoreceptor; Microdialysis; Monoamine; Noradrenaline; Reuptake; Striatum; Substantia nigra; Transporter

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2C ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATIPAMEZOLE; AUTORECEPTOR; CITALOPRAM; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; HALOPERIDOL; JO 1; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OXIDOPAMINE; PRAZOSIN; QUINELORANE; RACLOPRIDE; REBOXETINE; S 18616; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; AMPEROMETRY; ANIMAL MODEL; BRAIN STEM INJURY; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; DRUG EFFECT; DRUG MECHANISM; EXCITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; AUTORECEPTORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; EXTRACELLULAR FLUID; MALE; MICRODIALYSIS; NEURAL INHIBITION; NEURAL PATHWAYS; NOREPINEPHRINE; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE; SEROTONIN; SUBSTANTIA NIGRA;

EID: 10344228794     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2004.04.040     Document Type: Conference Paper

References (72)

1. E.D. Abercrombie, K.A. Keefe, D.S. DiFrischia, and M.J. Zigmond Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex J. Neurochem. 52 1989 1655 1658
2. Aston-Jones G, Shipley MT. Grzanna R. The locus coeruleus, A5 and A7 noradrenergic cell groups. In: The Rat Nervous System. Academic Press Inc.: 1995.
3. E.C. Azmitia, and M. Segal An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat J. Comp. Neurol. 179 1978 641 667
4. 1- adrenoceptor-mediated excitation of substantia nigra pars reticulata neurons Neuroscience 98 2000 599 604
5. C.W. Berridge, and B.D. Waterhouse The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes Brain Res. Brain Res. Rev. 42 2003 33 84
6. 2-adrenoceptor antagonists: a new approach to Parkinson's disease CNS Drugs 10 2003 189 207
7. E. Carboni, G.L. Tanda, R. Frau, and G. Di Chiara Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals J. Neurochem. 55 1990 1067 1070
8. M.A. Cenci, P. Kalen, R.J. Mandel, and A. Bjorklund Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res. 581 1992 217 228
9. 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate Br. J. Pharmacol. 130 2000 23 26
10. G. Di Chiara, G.L. Tanda, R. Frau, and E. Carboni Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers Neurochem. Int. 20 Suppl 1992 231S 235S
11. J.H. Fallon, and R.Y. Moore Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum J. Comp. Neurol. 180 1978 545 580
12. S.H. Fox, B. Henry, M.P. Hill, D. Peggs, A.R. Crossman, and J.M. Brotchie Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan Mov. Disord. 16 2001 642 650
13. M. Gesi, P. Soldani, F.S. Giorgi, A. Santinami, I. Bonaccorsi, and F. Fornai The role of the locus coeruleus in the development of Parkinson's disease Neurosci. Biobehav. Rev. 24 2000 655 668
14. 3H]dopa in various regions of the brain J. Neurochem. 13 1966 655 669
15. A. Gobert, J.M. Rivet, V. Audinot, A. Newman-Tancredi, L. Cistarelli, and M.J. Millan Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release Neuroscience 84 1998 413 429
16. J. Grenhoff, and T.H. Svensson Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area Eur. J. Pharmacol. 233 1993 79 84
17. P.J. Gresch, A.F. Sved, M.J. Zigmond, and J.M. Finlay Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex J. Neurochem. 65 1995 111 116
18. R. Grondin, T.A. Hadj, V.D. Doan, P. Ladure, and P.J. Bedard Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys Naunyn Schmiedebergs Arch. Pharmacol. 361 2000 181 186
19. P. Hertel, N. Lindblom, G.G. Nomikos, and T.H. Svensson Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action Prog. Neuropsychopharmacol. Biol. Psychiatry 22 1998 815 834
20. 1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release - I. BMY7378 and prazosin Neuropharmacology 34 1995 615 620
21. O. Hornykiewicz The role of dopamine (3-hydroxytyramine) in parkinsonism E. Trabbuchi E. Paoletti N. Canal Biochemical and Neurophysiological Correlations of Centrally Acting Drugs 1964 Pergamon Press Oxford 143 157
22. B.E. Jones, and R.Y. Moore Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res. 127 1977 25 53
23. 2-adrenoceptors modulating hippocampal norepinephrine release in rat. Brain Res. 674 1995 238 244
24. 2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype Neuropharmacology 44 2003 882 892
25. 2A-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo Proc. Natl. Acad. Sci. U S A 94 1997 9950 9955
26. A.J. Lategan, M.R. Marien, and F.C. Colpaert Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis Brain Res. 523 1990 134 138
27. A.J. Lategan, M.R. Marien, and F.C. Colpaert Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study Life Sci. 50 1992 995 999
28. 1A receptors Eur. J. Pharmacol. 260 1994 79 83
29. P. Levitt, and R.Y. Moore Origin and organization of brainstem catecholamine innervation in the rat J. Comp. Neurol. 186 1979 505 528
30. X.M. Li, K.W. Perry, D.T. Wong, and F.P. Bymaster Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum Psychopharmacology (Berl.) 136 1998 153 161
31. O. Lindvall, and A. Bjorklund The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method Acta Physiol. Scand. Suppl. 412 1974 1 48
32. 2A-adrenergic receptor by homologous recombination reveals the role of this receptor subtype in multiple physiological processes Adv. Pharmacol. 42 1998 493 496
33. M. Mavridis, A.D. Degryse, A.J. Lategan, M.R. Marien, and F.C. Colpaert Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease Neuroscience 41 1991 507 523
34. E.C. McGeer, G.M. Ling, and P.L. McGeer Convertion of tyrosine to catecholamine by cat brain in vivo Biochem. Biophys. Res. Comm. 13 1963 291 296
35. M.J. Millan Descending control of pain Prog. Neurobiol. 66 2002 355 474
36. M.J. Millan, M. Brocco, A. Gobert, R. Schreiber, and A. Dekeyne S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1- (4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol J. Pharmacol. Exp. Ther. 288 1999 1002 1014
37. 2-adrenoceptors: cellular and functional characterization J. Pharmacol. Exp. Ther. 297 2001 876 887
38. 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol J. Pharmacol. Exp. Ther. 286 1998 1341 1355
39. M.J. Millan, F. Lejeune, and A. Gobert Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents J. Psychopharmacol. 14 2000 114 138
40. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine J. Pharmacol. Exp. Ther. 295 2000 1206 1222
41. M.J. Millan, A. Newman-Tancredi, M. Brocco, A. Gobert, F. Lejeune, V. Audinot, J.M. Rivet, R. Schreiber, A. Dekeyne, M. Spedding, J.P. Nicolas, and J.L. Peglion S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride J. Pharmacol. Exp. Ther. 287 1998 167 186
42. R.Y. Moore, and J.P. Card Noradrenaline-containing neuron systems A. Bjorklund T. Hokfelt Handbook of Chemical Neuroanatomy: Classical Transmitters in the CNS, Part I 1984 Elsevier Amsterdam 123 156
43. J.A. Moron, A. Brockington, R.A. Wise, B.A. Rocha, and B.T. Hope Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines J Neurosci. 22 2002 389 395
44. 2-adrenoceptor J. Pharmacol. Exp. Ther. 303 2002 805 814
45. A.P. Nicholas, T. Hokfelt, and V.A. Pieribone The distribution and significance of CNS adrenoceptors examined with in situ hybridization Trends Pharmacol. Sci. 17 1996 245 255
46. 2 adrenergic receptor subtypes in rat brain: an in situ hybridization study J. Comp. Neurol. 328 1993 575 594
47. A. Oke, R. Keller, and R.N. Adams Dopamine and norepinephrine enhancement in discrete rat brain regions following neonatal 6-hydroxydopamine treatment Brain Res. 148 1978 245 250
48. L. Pozzi, R. Invernizzi, L. Cervo, F. Vallebuona, and R. Samanin Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats J. Neurochem. 63 1994 195 200
49. L. Pozzi, R. Invernizzi, C. Garavaglia, and R. Samanin Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram J. Neurochem. 73 1999 1051 1057
50. 2-adrenergic receptors in rat brain Proc. Natl. Acad. Sci. U S A 81 1984 1585 1589
51. 2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease Mov. Disord. 16 2001 708 713
52. 2 adrenergic subtypes J. Pharmacol. Exp. Ther. 270 1994 946 957
53. 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system J. Comp. Neurol. 372 1996 135 165
54. R.A. Ross, and D.J. Reis Effects of lesions of locus coeruleus on regional distribution of dopamine-beta-hydroxylase activity in rat brain Brain Res. 73 1974 161 166
55. L. Rouquier, Y. Claustre, and J. Benavides Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study Eur. J. Pharmacol. 261 1994 59 64
56. 2-adrenoceptor agonist Mol. Pharmacol. 51 1997 36 46
57. 2-adrenergic receptor subtype gene expression in rat brain Brain Res. Mol. Brain Res. 21 1994 133 149
58. S. Schroeter, S. Apparsundaram, R.G. Wiley, L.H. Miner, S.R. Sesack, and R.D. Blakely Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter J. Comp. Neurol. 420 2000 211 232
59. D. Shachar, E. Klein, A. Tabak, and J.P. Finberg Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain Eur. J. Pharmacol. 332 1997 237 243
60. L.W. Swanson, and B.K. Hartman The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker J. Comp. Neurol. 163 1975 467 505
61. 2A-adrenergic receptor-like immunoreactivity in the rat central nervous system J. Comp. Neurol. 372 1996 111 134
62. G. Tanda, E. Carboni, R. Frau, and G. Di Chiara Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl.) 115 1994 285 288
63. 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo Naunyn Schmiedebergs Arch. Pharmacol. 345 1992 137 143
64. 2A in the rabbit Naunyn Schmiedebergs Arch. Pharmacol. 348 1993 35 45
65. 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices Naunyn Schmiedebergs Arch. Pharmacol. 350 1994 473 481
66. 2-autoreceptors Naunyn Schmiedebergs Arch. Pharmacol. 349 1994 25 33
67. S. Udenfriend, and C.R. Creveling Localization of dopamine-beta-oxidase in brain J. Neurochem. 4 1959 350 352
68. M.J. van Veldhuizen, M.G. Feenstra, R.P. Heinsbroek, and G.J. Boer In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves Br J Pharmacol. 109 1993 655 660
69. D.H. Versteeg, G.J. Van Der, W. De Jong, and M. Palkovits Regional concentrations of noradrenaline and dopamine in rat brain. Brain Res. 113 1976 563 574
70. E.H. Wong, M.S. Sonders, S.G. Amara, P.M. Tinholt, M.F. Piercey, W.P. Hoffmann, D.K. Hyslop, S. Franklin, R.D. Porsolt, A. Bonsignori, N. Carfagna, and R.A. McArthur Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake-inhibitor Biol. Psychiatry. 47 2000 818 829
71. 2-adrenergic control of dopamine overflow and metabolism in mouse striatum Eur. J. Pharmacol. 339 1997 113 119
72. 2-adrenoceptor antagonist, augments the effects of l-DOPA on evoked dopamine release in rat striatum Eur. J. Pharmacol. 462 2003 83 89